Stockreport

Cerecor restarts early-stage CERC-002 study in Crohn’s disease [Seeking Alpha]

KIRIN HLDGS CO LTD S/ADR  (KNBWY) 
US:NASDAQ Investor Relations: kirinholdings.co.jp/english/ir
PDF Cerecor(NASDAQ:CERCresumedTop line data are expected in Q1 2021.CERC-002 is a fully human anti-LIGHT (TNFSF14) monoclonal antibody licensed from Kyowa Kirin Co., Ltd. It [Read more]